Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 4, 2011, Pages 575-581

  Maeda, K ^a   Ikeda, Y ^b   Fujita, T ^b   Yoshida, K ^a   Azuma, Y ^c   Haruyama, Y ^c   Yamane, N ^c   Kumagai, Y ^b   Sugiyama, Y ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

^c Nishiwaki Laboratory   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYTOCHROME P450 3A4; ITRACONAZOLE; MIDAZOLAM; ORGANIC ANION TRANSPORTER; PRAVASTATIN; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG UPTAKE; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; LIVER CLEARANCE; MALE; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL;

ADULT; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPTANOIC ACIDS; HUMANS; LIVER; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; ORGANIC ANION TRANSPORTERS; PRAVASTATIN; PYRROLES; TIME FACTORS; YOUNG ADULT;

EID: 80052968100     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.142     Document Type: Article

References (34)

1. Shitara, Y., Horie, T. & Sugiyama, Y. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 27, 425-446 (2006). (Pubitemid 43363338)
2. Kusuhara, H. & Sugiyama, Y. In vitro-in vivo extrapolation of transportermediated clearance in the liver and kidney. Drug Metab. Pharmacokinet. 24, 37-52 (2009).
3. Watanabe, T. et al. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab. Dispos. 38, 215-222 (2010).
4. Fuhr, U., Jetter, A. & Kirchheiner, J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin. Pharmacol. Ther. 81, 270-283 (2007). (Pubitemid 46174825)
5. Giacomini, K.M. et al.; International Transporter Consortium. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9, 215-236 (2010).
6. Lennernäs, H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet. 42, 1141-1160 (2003). (Pubitemid 37357650)
7. Pasanen, M.K., Fredrikson, H., Neuvonen, P.J. & Niemi, M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 82, 726-733 (2007). (Pubitemid 350114817)
8. Lau, Y.Y., Huang, Y., Frassetto, L. & Benet, L.Z. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol. Ther. 81, 194-204 (2007). (Pubitemid 46174816)
9. Nishizato, Y. et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73, 554-565 (2003). (Pubitemid 37249126)
10. Bertz, R.J. & Granneman, G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32, 210-258 (1997). (Pubitemid 27122521)
11. Vavricka, S.R., Van Montfoort, J., Ha, H.R., Meier, P.J. & Fattinger, K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36, 164-172 (2002). (Pubitemid 34700774)
12. Kato, M. et al. The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm. Res. 25, 1891-1901 (2008).
13. Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H. & Sugiyama, Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol. Rev. 50, 387-412 (1998).
14. Hirano, M., Maeda, K., Shitara, Y. & Sugiyama, Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab. Dispos. 34, 1229-1236 (2006).
15. Matsushima, S., Maeda, K., Ishiguro, N., Igarashi, T. & Sugiyama, Y. Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos. 36, 663-669 (2008). (Pubitemid 351468371)
16. Backman, J.T., Kivistö, K.T., Olkkola, K.T. & Neuvonen, P.J. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur. J. Clin. Pharmacol. 54, 53-58 (1998). (Pubitemid 28189400)
17. Olkkola, K.T., Backman, J.T. & Neuvonen, P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 55, 481-485 (1994). (Pubitemid 24192233)
18. Olkkola, K.T., Ahonen, J. & Neuvonen, P.J. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth. Analg. 82, 511-516 (1996). (Pubitemid 26072953)
19. Mazzu, A.L., Lasseter, K.C., Shamblen, E.C., Agarwal, V., Lettieri, J. & Sundaresen, P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin. Pharmacol. Ther. 68, 391-400 (2000).
20. Neuvonen, P.J., Kantola, T. & Kivistö, K.T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. 63, 332-341 (1998). (Pubitemid 28182231)
21. Kantola, T., Kivistö, K.T. & Neuvonen, P.J. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin. Pharmacol. Ther. 64, 58-65 (1998). (Pubitemid 28377331)
22. Deng, S. et al. Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. Clin. Ther. 31, 1256-1263 (2009).
23. Letschert, K., Faulstich, H., Keller, D. & Keppler, D. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol. Sci. 91, 140-149 (2006).
24. T irona, R.G., Leake, B.F., Wolkoff, A.W. & Kim, R.B. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampinmediated pregnane X receptor activation. J. Pharmacol. Exp. Ther. 304, 223-228 (2003). (Pubitemid 36008932)
25. T reiber, A., Schneiter, R., Häusler, S. & Stieger, B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab. Dispos. 35, 1400-1407 (2007). (Pubitemid 47121782)
26. Davies, B. & Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093-1095 (1993). (Pubitemid 23211439)
27. Boman, G. & Ringberger, V.A. Binding of rifampicin by human plasma proteins. Eur. J. Clin. Pharmacol. 7, 369-373 (1974).
28. Kohno, H., Hata, B., Tsuchiya, T., Kubo, H., Kobayashi, Y. Pharmacokinetics of rifampicin. Jpn. J. Clin. Pharmacol. Ther. 13 403-412 (1982).
29. Kajosaari, L.I., Laitila, J., Neuvonen, P.J. & Backman, J.T. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin. Pharmacol. Toxicol. 97, 249-256 (2005). (Pubitemid 41433700)
30. Lau, Y.Y., Okochi, H., Huang, Y. & Benet, L.Z. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J. Pharmacol. Exp. Ther. 316, 762-771 (2006). (Pubitemid 43131004)
31. Sahi, J. et al. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034. Chem. Biol. Interact. 159, 156-168 (2006). (Pubitemid 43042623)
32. Jacobsen, W. et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab. Dispos. 28, 1369-1378 (2000).
33. Kameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M. & Chiba, K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 15, 513-522 (2005). (Pubitemid 41017600)
34. Hisaka, A. & Sugiyama, Y. Analysis of nonlinear and nonsteady state hepatic extraction with the dispersion model using the finite difference method. J. Pharmacokinet. Biopharm. 26, 495-519 (1998). (Pubitemid 29157780)